Last A$3.05 AUD
Change Today -0.04 / -1.29%
Volume 20.6K
SOM On Other Exchanges
As of 10:27 PM 03/1/15 All times are local (Market data is delayed by at least 15 minutes).

somnomed ltd (SOM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/20/15 - A$3.20
52 Week Low
04/9/14 - A$1.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SOMNOMED LTD (SOM)

Related News

No related news articles were found.

somnomed ltd (SOM) Related Businessweek News

No Related Businessweek News Found

somnomed ltd (SOM) Details

SomnoMed Limited produces, commercializes, and sells devices for the oral treatment of sleep related disorders in the Asia Pacific, Europe, and the United States. The company provides diagnostic and treatment options for sleep-related breathing disorders, such as obstructive sleep apnea and sleep bruxism. Its products include SomnoDent, a medical oral appliance therapy for obstructive sleep apnea; and SomnoBrux to protect patient’s teeth against heaving grinding. The company was founded in 2004 and is based in Crows Nest, Australia.

250 Employees
Last Reported Date: 09/29/14
Founded in 2004

somnomed ltd (SOM) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: A$370.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: A$324.6K
President of Somnomed Inc
Total Annual Compensation: A$407.0K
Vice President ­ Global Production and Produc...
Total Annual Compensation: A$203.0K
Vice President ­ Marketing and Sales Europe
Total Annual Compensation: A$313.5K
Compensation as of Fiscal Year 2014.

somnomed ltd (SOM) Key Developments

SomnoMed Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2014; Provides Earnings Guidance for the Second Half and Year 2015

SomnoMed Limited reported unaudited consolidated earnings results for the six months ended December 31, 2014. For the period, the company’s revenue from sale of goods and services, net of discounts was AUD 14,819,277 against AUD 12,552,906 a year ago. Operating profit before corporate, research and business development expenses, non-cash items and income tax was AUD 1,754,470 against AUD 2,235,547 a year ago. Profit before income tax expense was AUD 77,817 against AUD 370,291 a year ago. Loss after income tax expense for the half year was AUD 45,127 against profit of AUD 8,603 a year ago. Profit for the half-year is attributable to owners of SomnoMed Limited was AUD 59,809 or 1.62 cents diluted per share against loss of AUD 160,602 or 0.37 cents diluted per share a year ago. Net cash outflow from operating activities was AUD 380,881 against AUD 446,314 a year ago. Payments for intangible assets were AUD 57,195 against AUD 75,000 a year ago. Payments for property, plant and equipment was AUD 575,161 against AUD 94,568 a year ago. EBITDA for the financial year of 2014-2015 is expected to rise fourfold or more in the second half, exceeding AUD 1.6 million, and generating an EBITDA of over AUD 2.0 million for the year. Profits in the second half will be an indicator of the likely profit growth to be expected in the future, after absorbing higher cost levels in the first half. For the second half of the financial year 2014-2015 the expected increase in unit volumes to 30,000 (increased 30.5% on corresponding period in the previous financial year) and revenues of AUD 18 million (increased 35% on corresponding period in the previous financial year) are unchanged. If achieved, it will lift the full year revenue growth rate to over 26%. The fall in the Australian dollar, which only occurred towards the end of the first half year, contributed minimally to the revenues in the first half year period but could see the revenue guidelines exceeded if this trend is maintained.

SomnoMed Limited Reports Sales Results for the Month, Second Quarter and Six Months Ended December 2014; Reaffirms Earnings Guidance for the First Half and Second Half of Fiscal 2015; Revises Earnings Guidance for the Fiscal 2015

SomnoMed Limited reported sales results for the month, second quarter and six months ended December 2014. Sales in December 2014 were over 5,000 units. The company reported second quarter of fiscal 2015 sales of 13,575 units. Strong growth was achieved in the US during the second quarter, which saw unit sales increase by over 30% compared to the same quarter in the previous year, and resulted in global volume growth for the second quarter of 21.8%. Total revenues generated in the first half of the financial year grew by 18% to $14.81 million. For the first half, sales totaled 24,775 units. Total revenues generated in the first half of the financial year grew by 18% to $14.81 million. As previously indicated, profit growth in the first half of fiscal 2015 will be lower than the growth in revenues, with start-up costs incurred in new markets in Europe and Asia, and expenditure relating to the global launch of new products. Guidance for the second half was based on the expectation of a further acceleration of its growth rates in volumes and revenues, leading to total sales of 30,000 units and revenues in the order of $18 million during the January to June 2015 period. This would result in volume growth of 30% in the second half and 26% for the year being achieved. Profits in the second half are likely to be in line with its expectations and will give an indication of the future earnings capability of SomnoMed. The company confirmed the forecast revenues of $32.5 million for the financial year of fiscal 2015. Given first half earnings, EBITDA for the year is expected to be consistent with its guidance but likely to come in towards the lower end of the range given.

SomnoMed Limited, Annual General Meeting, Nov 26, 2014

SomnoMed Limited, Annual General Meeting, Nov 26, 2014., at 11:00 AUS Eastern Standard Time. Location: Royal Room, Level 13, 167 Macquarie Street. Agenda: To consider and receive the Financial Report, the Directors' Report and the Auditor's Report for the year ended 30 June 2014; to adopt the Remuneration Report for the year ended 30 June 2014; to approve election of Robert Scherini as Director; to approve issue of Options to Belgove Pty Limited; to consider approval to issue a total of 200,000 ordinary shares to Belgove Pty Limited and P Neustadt Holdings Pty Ltd as trustee for Belgove Super Fund A/C (companies associated with Dr. Peter Neustadt- a Director of the Company) under a Placement; to consider approval to issue 50,000 ordinary shares to Leedoc Pty Limited (a company associated with Ms Lee Ausburn- a Director of the Company) under a placement; to consider ­approval to issue a total of 20,000 ordinary shares to Mr. Robert Scherini, as trustee for The East Trust under a Placement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOM:AU A$3.05 AUD -0.04

SOM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SOM.
View Industry Companies

Industry Analysis


Industry Average

Valuation SOM Industry Range
Price/Earnings 100.0x
Price/Sales 0.4x
Price/Book 7.3x
Price/Cash Flow 119.7x
TEV/Sales 4.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOMNOMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at